Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print      Mail a friend       Annual reports

Friday 16 March, 2012

Physiomics PLC

Physiomics to present at the Bio-Europe Conference

RNS Number : 4355Z
Physiomics PLC
16 March 2012
 



 

                                                                                               

Physiomics plc

("Physiomics") or ("the Company")

 

Physiomics to present at the Bio-Europe Spring Conference

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that that itwill be presenting at the 2012 Bio-Europe Spring 6th Annual International Partnering Conference, taking place at the Amsterdam RAI Convention Centre on 19th-21st March 2012.  Dr Mark Chadwick, Chief Executive Officer of Physiomics, will give an update on the Company's activities and recent progress, in particular the further development of Virtual Tumour and new services.  The presentation will be a part of the cancer track, scheduled at 9 am on Wednesday 21st March.

More information about the conference may be found at http://www.ebdgroup.com/bes

Enquiries:

 

Physiomics plc                                                  

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

 

 

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

 

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

 

 

 

About Physiomics plc

 

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

 

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

 

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALLFEFVAIELIF